Drug-specific and time-dependent risks of bacterial infection among patients with rheumatoid arthritis who were exposed to tumor necrosis factor α antagonists

Arthritis and Rheumatism

Volumn 56, Issue 12, 2007, Pages 4226-4227

  Curtis, Jeffrey R ^a   Xi, Juan ^a   Patkar, Nivedita ^a   Xie, Aiyuan ^a   Saag, Kenneth G ^a   Martin, Carolyn ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b Center for Health Care Policy and Evaluation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CYTOKINE RECEPTOR ANTAGONIST; ETANERCEPT; INFLIXIMAB; METHOTREXATE;

ARTICLE; BACTERIAL INFECTION; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG SAFETY; HUMAN; LONG TERM CARE; MORBIDITY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK FACTOR; SENSITIVITY ANALYSIS; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BACTERIAL INFECTIONS; HUMANS; IMMUNOGLOBULIN G; INCIDENCE; METHOTREXATE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; RISK FACTORS; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 37149005795     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23050     Document Type: Article

References (6)

1. Curtis JR, Patkar N, Xie A, Martin C, Allison JJ, Saag M, et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor α antagonists. Arthritis Rheum 2007;56:1125-33.
2. Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum 2006;54:628-34.
3. Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP, on behalf of the British Society for Rheumatology Biologies Register. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006;54:2368-76.
4. Listing J, Strangfeld A, Kary S, Rau R, von Hinueber U, Stoyanova-Scholz M, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005;52:3403-12.
5. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials [published erratum appears in JAMA 2006;295:2482]. JAMA 2006;295:2275-85.
6. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004;38:1261-5.